Salix Pharmaceuticals ( SLXP) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole was unchanged today. By the end of trading, Salix Pharmaceuticals rose $2.52 (5.1%) to $52.12 on heavy volume. Throughout the day, 1.7 million shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 889,900 shares. The stock ranged in a price between $50.48-$52.74 after having opened the day at $51.16 as compared to the previous trading day's close of $49.60. Other companies within the Health Care sector that increased today were: Arena Pharmaceuticals ( ARNA), up 25.7%, Savient Pharmaceuticals ( SVNT), up 16.7%, IsoRay ( ISR), up 14%, and K-V Pharmaceutical Company ( KV.B), up 11.7%. Salix Pharmaceuticals, Ltd. acquires, develops, and markets prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $2.81 billion and is part of the drugs industry. The company has a P/E ratio of 33.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 3.7% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold. TheStreet Ratings rates Salix Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.
- You can view the full Salix Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.